Lparomlimab & Tuvonralimab Injection (Qibeian) – 50?mg/2?mL Vial Price comparison
$1.00
Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination (PD?1/CTLA?4) developed by Qilu Pharmaceutical (QL1706), supplied as 50?mg in 2?mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use.
描述
Lparomlimab & Tuvonralimab Injection Product Specifications
| Attribute | Information |
|---|---|
| Product Name | Lparomlimab & Tuvonralimab Injection (Qibeian® / QL1706) |
| Formulation | Injection, 50?mg in 2?mL vial |
| Approval No. | China NMPA S20240044 |
| Drug Standard Code | 86904021005238 |
| Manufacturer | Qilu Pharmaceutical Co., Ltd. |
| Intended Use | For research use only, not for therapeutic use |
Lparomlimab & Tuvonralimab Background & Mechanism
Qibeian (QL1706) combines two antibodies—lparomlimab (anti-PD?1) and tuvonralimab (anti-CTLA?4)—in a single product. This dual blockade enhances T-cell activation through simultaneous PD?1/CTLA?4 pathway inhibition
Conditionally approved by NMPA in September 2024 for recurrent/metastatic cervical cancer post-platinum therapy
Lparomlimab & Tuvonralimab Clinical Highlights
-
Phase II (DUBHE?C?206): In recurrent/metastatic cervical cancer, objective response rate (ORR): 33.8%, disease control rate (DCR): 64.9%, median PFS: 5.4 months (148 patients)
-
Safety: 70.3% experienced treatment?related adverse events; 24.3% had grade ?3 TRAEs—most commonly anemia, thyroid dysfunction, GGT elevation
Research Applications
Ideal for preclinical and translational studies on:
-
Immune checkpoint inhibition
-
Tumor microenvironment research
-
Combination studies (e.g., with chemotherapy, targeted agents, radiotherapy)
-
Biomarker and pharmacodynamic assays
Storage & Handling
-
Storage: 2?–?8?°C, avoid freezing.
-
Handling: Use aseptic technique in a biosafety cabinet.
-
Stability: Per manufacturer instructions (CCF refrigerated vials).
? References
-
NMPA conditional approval announcement pubmed.ncbi.nlm.nih.gov+4english.nmpa.gov.cn+4english.nmpa.gov.cn+4
-
First approval review in Drugs journal biospace.com+15pubmed.ncbi.nlm.nih.gov+15bydrug.pharmcube.com+15
-
DUBHE?C?206 Phase II trial data delta.larvol.com+4biospace.com+4sohu.com+4
-
Preclinical combination studies bydrug.pharmcube.com+5biospace.com+5prnewswire.com+5
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 18 × 16 厘米 |
相关产品
-
Granisetron Hydrochloride Dispersible Tablets Price comparison
A 5-HT? receptor antagonist—Granisetron Hydrochloride Dispersible Tablets by Guangxi Mingjian Pharmaceutical Co., Ltd. (Guimingjian). Packaged as 1?mg tablets, 4 tablets per blister × 2 blisters per box. Approved in China (NMPA No. H20020303; product code 86905130000183). Primarily intended for clinical prevention and treatment of nausea/vomiting induced by chemotherapy, radiation, or surgery. For research use only $1.00 -
Toremifene Citrate Tablets (Ovry®) – 60?mg
Toremifene citrate (brand name Ovry®), manufactured by Jiangsu Ascend Pharmaceutical Co., Ltd., is a selective estrogen receptor modulator (SERM) approved in China (NMPA No.?H20243050, code?86901425001187). Each box contains 30 tablets (60?mg each) in 3 blister cards (barcode?6953272600284). Strictly for laboratory research purposes only. $1.00 -
Aprepitant Capsules (Kangrenping®) – 125?mg [For Laboratory Research Use Only]
Aprepitant Capsules (Kangrenping®), 125?mg ×1 + 80?mg ×2 per box. For laboratory research use only $1.00 -
Irinotecan Hydrochloride Liposome Injection (Du’EnYi®) – 10?mL:43?mg Vial
Irinotecan Hydrochloride Liposome Injection Du’EnYi® is China’s first domestically approved liposome-encapsulated irinotecan injection, equivalent to ONIVYDE®. Each 10?mL vial contains 43?mg irinotecan and is strictly for laboratory research use only—not for clinical or human application.?Please consult the staff for other purposes? $1.00
评价
目前还没有评价